All In Biotech

Drug Trial Radar · NCT01212991

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

PREVAIL: A MULTINATIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ORAL MDV3100 IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE METASTATIC PROSTATE CANCER WHO HAVE FAILED ANDROGEN DEPRIVATION THERAPY

Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,717

Actual

Start

Sep 16, 2010

Primary completion

Sep 30, 2013

Study completion Feb 14, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
First posted
Oct 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.

Conditions

  • Prostate Cancer

Interventions

  • EnzalutamideDrug

    Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.

  • PlaceboDrug

    Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: During study period (up to 3 years)
  2. Radiographic Progression-free Survival (rPFS)Time frame: During study period (up to 20 months)

Locations

269 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • The University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Cancer Certer-North Campus

    Tucson, Arizona

  • Cancer Center Oncology Medical Group

    La Mesa, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC&USC Medical Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services

    Los Angeles, California

  • UCLA Clark Urology Clinic

    Los Angeles, California

  • North County Oncology Medical Clinic, Inc

    Oceanside, California

  • UC Davis Medical Center

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Medical Oncology Associates-SD

    San Diego, California

  • Sharp Memorial Hospital Investigational Pharmacy

    San Diego, California

  • Sharp Rees-Stealy

    San Diego, California

  • Stanford University Medical Center

    Stanford, California

  • Anschutz Cancer Center Pavilion Pharmacy

    Aurora, Colorado

  • University of Colorado Hospital, Anschutz Cancer Pavilion

    Aurora, Colorado

  • Lynn Cancer Institute Center for Hematology Oncology

    Boca Raton, Florida

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Jewish Hospital & St. Mary's Healthcare, Inc.

    Louisville, Kentucky

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Beth Israel Deaoness Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Karmanos Cancer Institute Weisberg Cancer Treatment Center

    Farmington Hills, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Barnes-Jewish St. Peters Hospital

    City of Saint Peters, Missouri

  • Barnes-Jewish West County Hospital

    Creve Coeur, Missouri

  • BJH Pharmacy

    St Louis, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • The Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Cancer Centers of North Carolina

    Cary, North Carolina

  • Levine Cancer Institute

    Charlotte, North Carolina

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.